Pricing Log in Create free account
Saturday 17 October 2026 Export LXRX’s income statement to Excel — free account

Lexicon Pharmaceuticals, Inc.

LXRX Healthcare Biotechnology

Lexicon Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $49.8 million, up 60.2% from fiscal 2024. In the quarter to June 2026, revenue fell 97.6%, EPS fell 800.0%, free cash flow fell 154.1% and total debt fell 8.32%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

1.52 0.13 −7.88%
Market cap
$734.2M
P/E
0.0×
Fwd P/E
−12.1×
Dividend yield
—
F-score
4/9
Altman Z
−12.11
Beneish M
−1.17
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 2.72
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — 5 — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 49.96%

Capital & Financial Ratios $m

Market Cap 734.18
Revenue 41.47
Net Income (61.12)
Free Cash Flow (64.99)
Net Debt (139.17)
Current Ratio 13.37 (at or above 1.5: strong)
Debt/Equity 0.29 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (12.10) (negative: loss-making)
P/S ratio 16.04 (above 10: high)
P/B ratio 3.81
Past 5Y EPS Growth —
This Y EPS Growth (20.12%) (below 0%: weak)
Next Y EPS Growth (26.11%) (below 0%: weak)
Next Y revenue growth (25.37%) (below 0%: weak)
Next 5Y EPS Growth 6.72%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 12.8×, against a ten-year median of 12.9×; over the ten years it ranged from 0.6× in 2020 to 4,508× in 2023.
P/S against its own 10 years 53.04%
10-year low 10-year high
P/B against its own 10 years 44.35%
10-year low 10-year high
EV/Sales against its own 10 years 46.33%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 170 238 96 191
Receivables 1 3 2 2
Inventory 0 0 0 1
Other — — — —
177 246 102 197
2023 2024 2025 Q'26
Payables 14 15 3 2
ST’ Debt — — 5 —
Other — — — —
32 45 21 15

Compound Annual Growth %

10y 5y 3y
Sales (9.15%) 15.72% 610.25%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (9.31%) (7.21%) (2.81%)

Revenue $m

Mar Jun Sep Dec Year
’26 21 1 — — —
’25 1 29 14 5 50
’24 1 2 2 27 31
’23 0 0 0 1 1
’22 0 0 0 0 0
’21 0 0 0 0 0
’20 8 9 7 0 24
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (15) (9) — — —
’25 (44) 17 (24) (17) (68)
’24 (55) (49) (54) (21) (179)
’23 (32) (38) (42) (51) (162)
’22 (23) (24) (19) (22) (89)
’21 (25) (22) (17) (23) (87)
’20 (22) (46) (40) (34) (143)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (15) (9) — — —
’25 (44) 17 (24) (17) (68)
’24 (55) (49) (54) (22) (180)
’23 (32) (38) (42) (51) (162)
’22 (23) (24) (19) (23) (90)
’21 (25) (23) (17) (23) (88)
’20 (22) (46) (40) (23) (132)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.00 (0.07) — — —
’25 (0.07) 0.01 (0.04) (0.04) (0.14)
’24 (0.20) (0.17) (0.18) (0.09) (0.63)
’23 (0.17) (0.22) (0.21) (0.20) (0.79)
’22 (0.16) (0.16) (0.13) (0.16) (0.62)
’21 (0.15) (0.13) (0.16) (0.17) (0.60)
’20 (0.63) (0.65) 0.71 (0.04) (0.53)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.7
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 7.65 8.07 6.02 1.13 1.03 3.26 1.31 0.92 0.62 0.28

Analyst estimates 2026–2028

Powerpack
High 19.62 18.00 13.97 8.39 4.47 9.65 3.99 3.79 3.73 1.66
People
People Employees 168 174 202 184 78 87 135 285 103 81
Revenue/emp, $m 0.47 0.53 0.31 1.75 0.31 0.00 0.00 0.00 0.30 0.61
Income, $m
Income, $m Revenue 79 92 63 322 24 0 0 1 31 50
Gross margin, % 100.00 97.93 96.06 99.00 91.96 100.00 100.00 92.94 98.02 99.45
EBT (131) (136) (121) 124 (59) (88) (102) (177) (200) (50)
EBT margin, % (165.85) (147.95) (190.71) 38.54 (244.11) (29,448.99) (73,341.01) (14,710.88) (644.78) (101.08)
Net income (131) (123) (121) 130 (59) (88) (102) (177) (200) (50)
Depreciation 3 4 5 5 4 0 1 2 2 2
Per share, $
Per share, $ Revenue 0.76 0.87 0.60 3.03 0.22 0.00 0.00 0.01 0.10 0.14
Earnings (1.36) (1.23) (1.14) 1.23 (0.53) (0.60) (0.62) (0.79) (0.63) (0.14)
Cash flow (1.69) (1.76) (1.40) 1.07 (1.29) (0.60) (0.54) (0.73) (0.56) (0.19)
Capex 0.00 0.00 0.00 0.00 0.10 (0.01) (0.01) 0.00 0.00 0.00
Free cash flow (1.69) (1.76) (1.41) 1.07 (1.19) (0.61) (0.54) (0.73) (0.56) (0.19)
Book value 1.52 0.65 (0.25) 1.10 1.41 0.78 0.71 0.42 0.46 0.30
Shares, m 104 105 106 106 111 146 166 221 320 363
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 3.40 0.00 0.00 0.00 0.00 0.00 0.00
P/S 18.61 11.62 11.12 1.37 15.80 1,925.73 2,372.72 292.02 7.62 8.38
P/B 9.37 15.60 0.00 3.76 2.42 5.05 2.82 3.78 1.62 3.88
EV/Sales 15.52 10.91 12.46 1.29 9.96 1,642.30 1,736.13 234.53 3.23 7.54
EV/FCF (6.99) (5.39) (5.30) 3.64 (1.81) (5.55) (2.68) (1.74) (0.56) (5.45)
Cash, $m
Cash, $m Operating cash flow (176) (185) (149) 114 (143) (87) (89) (162) (179) (68)
Capex 0 0 0 0 11 (1) (1) 0 (1) —
Free cash flow (176) (186) (149) 114 (132) (88) (90) (162) (180) (68)
Balance, $m
Balance, $m Working capital 193 217 137 272 111 67 118 145 201 81
Total debt 101 246 245 245 12 2 50 100 100 54
Net debt (245) (65) 85 (26) (140) (84) (88) (71) (138) (42)
Shareholders’ equity 157 68 (26) 117 156 114 117 93 146 108
Returns, %
Returns, % ROA (23.31) (26.97) (33.45) 37.08 (18.85) (51.52) (61.56) (83.60) (75.93) (20.83)
ROIC 0.00 (2,594.22) (110.26) 97.55 (182.69) (186.85) (219.91) (475.14) (1,485.93) (46.81)
ROE (59.31) (109.00) (575.96) 286.97 (42.84) (65.01) (88.37) (168.50) (167.66) (39.72)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Lexicon Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SANA Sana Biotechnology, Inc. $740.9M — (loss-making) — — n/m −5.46% (below 0%: shrinking) 0.00% 0.00% Compare
IVA Inventiva S.A. Sponsored ADR $740.0M — (loss-making) — (loss-making) −10.77% (below 0%: shrinking) n/m −20,989.22% (below 0%: shrinking) 0.00% 0.00% Compare
LXRX Lexicon Pharmaceuticals, Inc. $734.2M — (loss-making) — (loss-making) −97.60% (below 0%: shrinking) n/m −154.09% (below 0%: shrinking) 94.36% (3,835.26%)
IMMX Immix Biopharma, Inc. $719.6M — (loss-making) — — n/m −116.22% (below 0%: shrinking) — 0.00% Compare
ACHV Achieve Life Sciences, Inc. $717.2M — (loss-making) — +54.44% (above 0%: growing) n/m −19.01% (below 0%: shrinking) 0.00% 0.00% Compare
FDMT 4D Molecular Therapeutics, Inc. $711.0M — (loss-making) — (loss-making) +25,106.67% (above 0%: growing) n/m −61.28% (below 0%: shrinking) 100.00% (2,037.16%) Compare
ANL Adlai Nortye Ltd. Sponsored ADR $710.1M — — — — +46.03% (above 0%: growing) — — Compare
OABI OmniAb, Inc. $687.7M — (loss-making) — (loss-making) +244.24% (above 0%: growing) n/m +211.16% (above 0%: growing) 95.45% (49.47%) Compare
ANNX Annexon, Inc. $682.5M — (loss-making) — — n/m −26.41% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $714.1M — — +149.34% — −22.71% 0.00% 0.00%

All 614 Biotechnology stocks →

Lexicon Pharmaceuticals, Inc. (LXRX) key facts

  • Strength: Lexicon Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $49.8 million, up 60.2% from fiscal 2024.
  • Lexicon Pharmaceuticals, Inc. (LXRX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, LXRX traded at $1.52, a market capitalization of $734.2 million.
  • Return on equity was −39.7% and debt-to-equity 0.29.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −12.11 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Lexicon Pharmaceuticals, Inc. (LXRX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/LXRX · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com